IL6 and cystic neoplasm: High levels of inflammatory mediators (e.g., IL6, IL8, IL1) have been observed in ACP in both the cystic and solid components, and targeting with the IL6 inhibitor Tocilizumab has shown modest responses in cystic tumours and is under evaluation in clinical trials (NCT05233397) [8, 22, 24].